Coronary Angioplasty with Drug-Eluting Stents: Device Costs, Hospital Costs, and Insurance Payments

Technology (BCHT) has been working with the Integrated Healthcare Association (IHA) on its Value–Based Purchasing of Medical Devices (VBP) project, which has included the collection and analysis of hospital and patient data on seven major orthopedic, cardiac, and spine procedures. This Issue Brief is the fi fth in a series that comes out of this project and presents fi ndings on implant costs, total surgical costs, complications, and insurance reimbursement for coronar y angioplasty with drug-eluding stents. Forty-fi ve hospitals in California participated in the full collection initiative, providing data on device costs, total procedure costs, complications,length of stay, reimbursements, and patient characteristics. Of these hospitals, only 27 had interventional cardiology programs; the data presented here are from these institutions. Hospital participants are diverse in terms of whether they belong to a multi-hospital system, urban or rural location, for-profi t or non-profi t status, teaching status, and bed size. All data are from 2008.